EAM
NVO

Eukles Asset Management’s Novo Nordisk NVO Stock Holding History

Eukles Asset Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.41M Sell
50,243
-684
-1% -$29.4K 0.99% 34
2026
Q1 		$1.87M Sell
50,927
-2,006
-4% -$95K 0.83% 40
2025
Q4 		$2.69M Hold
52,933
– – 1.05% 29
2025
Q3 		$2.94M Sell
52,933
-782
-1% -$45.8K 1.14% 26
2025
Q2 		$3.71M Buy
53,715
+2,403
+5% +$163K 1.52% 18
2025
Q1 		$3.56M Buy
51,312
+1,667
+3% +$138K 1.56% 20
2024
Q4 		$4.27M Sell
49,645
-3,939
-7% -$426K 1.82% 14
2024
Q3 		$6.38M Sell
53,584
-371
-0.7% -$49.5K 2.56% 9
2024
Q2 		$7.7M Sell
53,955
-378
-0.7% -$50.1K 3.33% 5
2024
Q1 		$6.98M Sell
54,333
-1,598
-3% -$190K 3.03% 6
2023
Q4 		$5.79M Sell
55,931
-2,754
-5% -$272K 2.74% 8
2023
Q3 		$5.34M Buy
58,685
+415
+0.7% +$36.6K 2.82% 7
2023
Q2 		$4.71M Buy
58,270
+58
+0.1% +$4.74K 2.41% 8
2023
Q1 		$4.63M Sell
58,212
-540
-0.9% -$38.3K 2.52% 8
2022
Q4 		$3.98M Buy
58,752
+408
+0.7% +$23.9K 2.32% 12
2022
Q3 		$2.91M Sell
58,344
-186
-0.3% -$9.96K 1.9% 14
2022
Q2 		$3.26M Buy
58,530
+182
+0.3% +$10.1K 2.06% 14
2022
Q1 		$3.24M Sell
58,348
-658
-1% -$33.8K 1.76% 17
2021
Q4 		$3.3M Buy
59,006
+1,120
+2% +$60.7K 1.6% 20
2021
Q3 		$2.78M Buy
57,886
+1,990
+4% +$96.2K 1.52% 25
2021
Q2 		$2.34M Buy
55,896
+3,986
+8% +$155K 1.3% 29
2021
Q1 		$1.75M Buy
51,910
+1,122
+2% +$40K 1.13% 37
2020
Q4 		$1.77M Buy
50,788
+1,204
+2% +$41.6K 1.23% 34
2020
Q3 		$1.72M Buy
49,584
+598
+1% +$19.9K 1.34% 31
2020
Q2 		$1.6M Buy
48,986
+2,894
+6% +$92.3K 1.36% 31
2020
Q1 		$1.39M Sell
46,092
-2,082
-4% -$62K 1.45% 27
2019
Q4 		$1.39M Sell
48,174
-494
-1% -$13.7K 1.14% 38
2019
Q3 		$1.26M Sell
48,668
-138
-0.3% -$3.49K 1.09% 41
2019
Q2 		$1.25M Sell
48,806
-238
-0.5% -$5.88K 1.08% 40
2019
Q1 		$1.28M Buy
49,044
+196
+0.4% +$4.82K 1.17% 40
2018
Q4 		$1.13M Buy
+48,848
New +$1.09M 1.17% 40

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Eukles Asset Management's NVO Position: Q2 2026 in Review

Eukles Asset Management reduced its Novo Nordisk (NVO) stake by 1.3% in Q2 2026, selling an estimated $29.4K and leaving 50,243 shares worth $2.41M. The position accounts for 0.99% of the portfolio, ranked #34.

Eukles Asset Management first reported a position in NVO in Q4 2018 and has held it in 31 quarters since. The position peaked at $7.7M in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Eukles Asset Management held 50,243 shares of Novo Nordisk worth $2.41M as of Q2 2026.
  • Eukles Asset Management sold 684 Novo Nordisk shares in Q2 2026, an estimated $29.4K.
  • Novo Nordisk made up 0.99% of Eukles Asset Management's portfolio in Q2 2026, its #34 holding.
  • Eukles Asset Management first reported a position in Novo Nordisk in Q4 2018 and has held it in 31 quarters since.
  • Eukles Asset Management's Novo Nordisk position peaked at $7.7M in Q2 2024.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Eukles Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.